Holen Sie sich die Stockscreener-App
79.57
0.54%
0.43
Handel nachbörslich:
79.57
Schlusskurs vom Vortag:
$79.14
Offen:
$78.58
24-Stunden-Volumen:
451.45K
Relative Volume:
0.57
Marktkapitalisierung:
$6.50B
Einnahmen:
$39.21M
Nettoeinkommen (Verlust:
$-311.35M
KGV:
-21.63
EPS:
-3.6793
Netto-Cashflow:
$-234.34M
1W Leistung:
+2.67%
1M Leistung:
-8.01%
6M Leistung:
+61.96%
1J Leistung:
+134.93%
1-Tages-Spanne:
$76.85
$80.66
1-Wochen-Bereich:
$76.85
$82.46
52-Wochen-Spanne:
$19.45
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
79.57 | 6.46B | 39.21M | -311.35M | -234.34M | -3.6793 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Fortgesetzt | Guggenheim | Buy |
| 2025-10-24 | Bestätigt | B. Riley Securities | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Nextech Invest Sells $4.19M in Kymera Shares, Stake Value Rises to $21.7MNews and Statistics - IndexBox
Nextech Trims Kymera at a Recent High — think Foolishly before acting. - Yahoo Finance
Aug Selloffs: What is the long term forecast for Kymera Therapeutics Inc stock2026 Market Sentiment & Pattern Based Trade Signal System - baoquankhu1.vn
Aug Breakouts: What is Kymera Therapeutics Incs 5 year growth outlookPortfolio Return Report & Consistent Return Strategy Ideas - baoquankhu1.vn
Weekly Earnings: Is Kymera Therapeutics Inc currently under institutional pressure2026 Price Momentum & Smart Investment Allocation Insights - baoquankhu1.vn
HighVista Strategies LLC Makes New $890,000 Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Holocene Advisors LP Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
KYMR: Jefferies Lowers Price Target but Maintains Buy Rating | KYMR Stock News - GuruFocus
Jefferies Financial Group Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
KYMR: Jefferies Lowers Price Target but Maintains Buy Rating | K - GuruFocus
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2025 earnings call transcript - MSN
Boxer Capital Management LLC Lowers Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Checkpoint Capital L.P. - MarketBeat
Braidwell LP Takes $15.66 Million Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside - Yahoo Finance
Kymera Therapeutics, Inc. $KYMR Stock Position Lessened by Avoro Capital Advisors LLC - MarketBeat
Can Kymera Therapeutics’ (KYMR) Oral Degraders Redefine Its Long-Term Edge Over Biologic Rivals? - simplywall.st
Kymera at Barclays Conference: Strategic Focus on Immunology By Investing.com - Investing.com Canada
KYMR: Advancing oral immunology therapies with robust pipeline and strong financial runway - TradingView
Kymera Therapeutics CFO presents new immunology strategy at Barclays Healthcare Conference - Traders Union
Morgan Stanley maintains Kymera Therapeutics (KYMR) overweight recommendation - MSN
Kymera Therapeutics, Inc. $KYMR Holdings Trimmed by Atika Capital Management LLC - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 25,758 Shares - MarketBeat
Kymera Therapeutics COO Sells Shares Worth Over $2 Million - TradingView
Kymera (NASDAQ: KYMR) COO exercises 20,000 options and sells 25,758 shares - Stock Titan
Jeremy Chadwick reports KYMR transactions (NASDAQ: KYMR) including 20,000-option line - Stock Titan
Hedge Fund Moves: Can Kymera Therapeutics Inc weather a recessionVolume Spike & Daily Chart Pattern Signals - baoquankhu1.vn
Kymera to present atopic dermatitis trial data at AAD meeting By Investing.com - Investing.com Canada
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621 - MSN
Kymera at Leerink Global Healthcare: Strategic Insights on Drug Development By Investing.com - Investing.com Canada
KYMR: KT-621 shows strong early efficacy and safety; pivotal Phase 2b readouts expected in 2027 - TradingView
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology Annual Meeting - Investing News Network
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting - Bitget
Experimental atopic dermatitis pill KT-621 heads to late-breaking AAD stage - Stock Titan
A Look At Kymera Therapeutics (KYMR) Valuation After Equity Raise, Wider Losses And Leadership Change - Sahm
Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss - Yahoo Finance
Market Moves: What is the long term forecast for Kymera Therapeutics Inc. stockWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
How (KYMR) Movements Inform Risk Allocation Models - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Profit Recap: How sensitive is Kymera Therapeutics Inc to inflationWeekly Volume Report & Reliable Entry Point Trade Alerts - baoquankhu1.vn
JPMorgan Chase & Co. Has $10.91 Million Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Q1 EPS Estimate for Kymera Therapeutics Boosted by Analyst - MarketBeat
Kymera (KYMR) Q4 2025 Earnings Call Transcript - AOL.com
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 3,919 Shares - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Insider Jared Gollob Sells 4,895 Shares - MarketBeat
Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet - AOL.com
Bruce Jacobs Sells 7,576 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Jared Gollob Sells 5,613 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 81,866 Shares of Stock - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Acquired by Rafferty Asset Management LLC - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $128.00 - MarketBeat
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):